![Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients | medRxiv Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2021/10/14/2021.10.14.21264981/F1.large.jpg)
Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients | medRxiv
![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/62ba4745-8f48-4fd3-a2fb-4d864c9277e3/gr5_lrg.jpg)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ... Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ...](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7113e2_JJBoosterVE_IMAGE_29March22_1200x675.jpg?_=89755)
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults ...
![Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/378/bmj-2022-070483/F2.medium.jpg)
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
![Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/asset/3b4eb078-d7dd-4a37-98ea-553c444f2a49/gr1.jpg)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Govt panel likely to decide on Covovax as a heterologous booster dose for adults on Wednesday, ET HealthWorld
![Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health](https://www.thelancet.com/cms/attachment/b7470a81-2935-4740-9fb4-c532d912c682/gr1_lrg.gif)
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
![Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_754645_16903578774359511.jpg)
Heterologous booster schedules are associated with increased protection against severe, omicron related COVID-19 outcomes
![Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ](https://www.bmj.com/content/bmj/382/bmj-2022-074325/F6.large.jpg)
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ
![Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/70ac421e-169c-4581-b03c-4ee839310ea2/gr1.jpg)
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people - The Lancet Infectious Diseases
![iNCOVACC World's first Intranasal Vaccine to receive both Primary series & Heterologous booster approval | DD News iNCOVACC World's first Intranasal Vaccine to receive both Primary series & Heterologous booster approval | DD News](https://ddnews.gov.in/sites/default/files/covid_55.jpg)
iNCOVACC World's first Intranasal Vaccine to receive both Primary series & Heterologous booster approval | DD News
![Covovax booster dose: DGCI approves Covid-19 vaccine Covovax as heterologous booster dose - The Economic Times Covovax booster dose: DGCI approves Covid-19 vaccine Covovax as heterologous booster dose - The Economic Times](https://img.etimg.com/thumb/width-1200,height-1200,imgsize-1073173,resizemode-75,msid-97038353/industry/healthcare/biotech/pharmaceuticals/dgci-approves-covid-19-vaccine-covovax-as-heterologous-booster-dose.jpg)
Covovax booster dose: DGCI approves Covid-19 vaccine Covovax as heterologous booster dose - The Economic Times
![Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study - Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study -](https://www.thelancet.com/cms/asset/9d78c591-56a3-4f67-bb91-52f440d63dcd/gr1.jpg)